As a result of the enhanced targetability between the platelet membrane and cancer cells, the therapeutic efficacy of TRAIL and doxorubicin was improved, resulting in increased apoptosis and tumour growth inhibition [126]. The gene discussed is TNFSF10; the disease is neoplasm.